Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK

INTRODUCTION: International guidelines recommend treatment with a sodium-glucose cotransporter-2 (SGLT-2) inhibitor or glucagon-like peptide-1 (GLP-1) receptor agonist for treatment intensification in type 2 diabetes mellitus (T2DM) patients with progression on metformin. In the randomised, controll...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Diabetes Ther
Auteurs principaux: Ramos, Mafalda, Cummings, Michael H., Ustyugova, Anastasia, Raza, Syed I., de Silva, Shamika U., Lamotte, Mark
Format: Artigo
Langue:Inglês
Publié: Springer Healthcare 2020
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7434815/
https://ncbi.nlm.nih.gov/pubmed/32700188
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-020-00883-1
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires